NEW YORK, Jan. 10 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX), Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co.
KgaA, and Merz Pharmaceuticals GmbH announced that they have filed lawsuits
in the U.S. District Court for the District of Delaware against several
companies for infringement of U.S. Patent No. 5,061,703 (the '703 patent),
which relates to Forest's Namenda(R) product. The defendants named in the
lawsuits include Barr Laboratories, Inc., Cobalt Laboratories, Inc., Lupin
Ltd., Orchid Chemicals & Pharmaceuticals Ltd., Teva Pharmaceuticals USA,
Inc., Upsher-Smith Laboratories Inc., Wockhardt Ltd., and related companies
and subsidiaries thereof. The '703 patent expires in April 2010. Forest has
applied for patent term extension which, if granted, would extend the '703
patent until September 2013.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
As previously reported, Forest had received notification from several
companies that they had filed Abbreviated New Drug Applications with
Paragraph IV certifications to obtain approval to market generic versions
of Namenda.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform act of 1995. These statements involve a number
of risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical products, the
impact of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to time in
each of Forest Laboratories' Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, and any subsequent SEC filings.
SOURCE Forest Laboratories, Inc.
 back to top
Related links:
http://www.frx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Charles E. Triano, Vice President, Investor
Relations of Forest Laboratories, Inc., +1-212-224-6714,
charles.triano@frx.com
|
